Antibiotic treatment failure

Abstract

This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.

Full Text

Restricted Access

About the authors

Sergey P. Alpatov

N.I. Pirogov Russian National Research Medical University

Email: immunosport@rambler.ru
ORCID iD: 0000-0003-2233-7301

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Nadezhda V. Bogush

N.I. Pirogov Russian National Research Medical University

Email: nadinbogush@gmail.com
Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Denis A. Borozdenko

N.I. Pirogov Russian National Research Medical University

Email: borozdenko@phystech.edu
ORCID iD: 0000-0002-6797-9722
Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Natalia M. Buyanova

N.I. Pirogov Russian National Research Medical University

Email: natasha-buyanova@mail.ru
ORCID iD: 0000-0002-4073-475X
Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Irina V. Ganshina

N.I. Pirogov Russian National Research Medical University

Email: july1119661@rambler.ru
ORCID iD: 0000-0003-4049-7907
Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Gulnara O. Dibirova

N.I. Pirogov Russian National Research Medical University

Email: g.dibirova@mail.ru
ORCID iD: 0000-0002-1500-4974

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Natalia B. Dmitrieva

N.I. Pirogov Russian National Research Medical University

Email: natapharm@gmail.com
Scopus Author ID: 7101760859

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Elena V. Kalinina

N.I. Pirogov Russian National Research Medical University

Email: lena_vk@mail.ru
Scopus Author ID: 8958305800

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Anna V. Kirillova

N.I. Pirogov Russian National Research Medical University

Email: kirillova6@yandex.ru
ORCID iD: 0000-0003-3966-4448

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Nina M. Kiseleva

N.I. Pirogov Russian National Research Medical University

Author for correspondence.
Email: kiseleva.67@mail.ru
ORCID iD: 0000-0003-1754-9051

MD, Dr. Sci. (Biol.), Professor

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

German V. Kukushkin

N.I. Pirogov Russian National Research Medical University

Email: germanpharm@yandex.ru
ORCID iD: 0000-0002-1661-1071

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Tatiana I. Leonteva

N.I. Pirogov Russian National Research Medical University

Email: leontevati@mail.ru

MD, Cand. Sci. (Biol.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Maxim L. Maximov

N.I. Pirogov Russian National Research Medical University

Email: maksim_maksimov@mail.ru
ORCID iD: 0000-0002-8979-8084

MD, Dr. Sci. (Med.), Professor

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Elena V. Markina

N.I. Pirogov Russian National Research Medical University

Email: elvikmark2015@yandex.ru
ORCID iD: 0000-0002-5943-4423
Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Svetlana E. Mileshina

N.I. Pirogov Russian National Research Medical University

Email: svetikshrv@rambler.ru
ORCID iD: 0000-0001-8082-9393

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Maia D. Tsitsuashvili

N.I. Pirogov Russian National Research Medical University

Email: mayan318@gmail.com
ORCID iD: 0000-0001-7761-8683

MD, Cand. Sci. (Biol.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

Dmitry E. Yurov

N.I. Pirogov Russian National Research Medical University

Email: dmpharm@gmail.com
ORCID iD: 0000-0003-0178-8736

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova str., 117997, Moscow

References

  1. Evteev VA, Muslimova OV, Mazerkina IA, et al. Organic anion transporters and their influence on the toxicity of β-lactam antibiotics. Bezopasnost' i risk farmakoterapii. 2017;5(2):70–75. (In Russ).
  2. Molchan NV, Smirnova YA, Vel'ts NY, et al. Fluoroquinolone antibiotics: safety of use by the example of ciprofloxacin. Bezopasnost' i risk farmakoterapii. 2019;7(2):72–83. (In Russ). doi: 10.30895/2312-7821-2019-7-2-72-83
  3. Ortenberg EA, Khokhlyavina RM, Shpil'kina LV, Khokhlyavin RL. Local antibiotic resistance in a multidisciplinary state: is an annual assessment sufficient? Ural'skii meditsinskii zhurnal. 2007;(6):54–58. (In Russ).
  4. Ostroumova OD, Kochetkov AI, Pavleeva EE, Kravchenko EV. Drug-Induced Neutropenia and Agranulocytosis. Bezopasnost' i risk farmakoterapii. 2020;8(3):109–122. (In Russ). doi: 10.30895/2312-7821-2020-8-3-109-122
  5. Ostroumova OD, Shahova EY, Kochetkov AI. Drug-Induced Eosinophilia. Bezopasnost' i risk farmakoterapii. 2019;7(4):176–189. (In Russ). doi: 10.30895/2312-7821-2019-7-4-176-189
  6. Postnikov SS, Teplova NV, Nikolaev VV, et al. A Case of Multiple Antibiotic-Associated Hepatotoxicity in an Infant. Bezopasnost' i risk farmakoterapii. 2019;7(3):146–151. (In Russ). doi: 10.30895/2312-7821-2019-7-3-146-151
  7. Reshet'ko OV, Yakimova YN, Novokreshchenova IG. Antibacterials for systemic use as reflected in formularies at different levels. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo. 2016;(3):62–66. (In Russ).
  8. Titova AR, Pasternak EY, Asetskaya L, et al. On the safety of antibacterial drugs used in pediatrics. Bezopasnost' i risk farmakoterapii. 2015;(2):12–22. (In Russ).
  9. Yakovlev S. Modern problems of antibiotic resistance in the hospital. Vrach. 2007;(1):9–12. (In Russ).
  10. elibrary [Internet]. Nauchnaya elektronnaya biblioteka [cited 25 Feb 2021]. Available from: https://elibrary.ru
  11. ncbi.nlm.nih.gov [Internet]. PubMed [cited 25 Feb 2021]. Available from: https://pubmed.ncbi.nlm.nih.gov
  12. Clinicaltrials [Internet]. Clinicaltrials [cited 25 feb 2021]. Available from: https://clinicaltrials.gov
  13. vigilyze [Internet]. Vigilyze [cited 25 Feb 2021]. Available from: https://vigilyze.who-umc.org
  14. Solodukhina OA, Verlan NV, Kochkina EO, Rozhkova NY. Monitoring of antibacterial drug safety in clinical practice. Izvestiya vuzov. Prikladnaya khimiya i biotekhnologiya. 2018;8(2):117–124. (In Russ). doi: 0.21285/2227-2925-2018-8-2-117-124

Supplementary files

Supplementary Files
Action
1. Fig. 1. VigiLyze data on antibiotic failure from 2018 to 2020.

Download (106KB)

Statistics

Views

Abstract: 145

PDF (Russian): 2

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2021 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies